Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: Biodistribution, pharmacokinetic and cytotoxicity study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kush, Preeti | - |
dc.contributor.author | Kaur, Manjot | - |
dc.contributor.author | Sharma, Monika | - |
dc.contributor.author | Madan,Jitender | - |
dc.contributor.author | Kumar, Parveen | - |
dc.contributor.author | Deep, Akash | - |
dc.contributor.author | Kim, Ki-Hyun | - |
dc.date.accessioned | 2021-08-02T09:51:19Z | - |
dc.date.available | 2021-08-02T09:51:19Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2057-1976 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10572 | - |
dc.description.abstract | Gemcitabine (GEM), a nucleoside analogue, is used for the treatment of various cancers. However, this drug possesses several limitations such as poor pharmacokinetics, metabolic degradation by cytidine deaminase, development of drug resistance, and schedule dependent toxicity. To circumvent these drawbacks, it can be entrapped in a suitable formulation for protection against metabolic degradation or urinary excretion. To this end, we have synthesized and investigated different iron (Fe-III)-based biocompatible metal-organic frameworks (MOFs), namely, MIL-101-NH2 (rigid), MIL-88A, and MIL-53 (flexible). All these MOFs have different topologies, connectivity, and chemical composition. MIL-53 was identified as a promising carrier for GEM delivery, with enhanced encapsulation and progressive release in relation to other candidates. The release of GEM from MIL-53 followed zero order kinetics, leading to an effective plasma concentration within the therapeutic range. Furthermore, in- vitro cytotoxicity study by using pancreatic cancer cell lines (MIAPaCa-2 and PANC1) stipulated that GEM loaded in MIL-53 (MIL53-GEM) had an increased cytotoxic effect relative to native GEM. Additionally, the slow release of GEM in a controlled manner could protect the drug from enzymatic degradation to increase its efficacy, half-life, and bioavailability without toxicity to organs as evidenced by in-vivo studies. This study demonstrates the potential of MIL53-GEM in upgrading the clinical outcome of GEM-based chemotherapy against cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Institute of Physics Publishing | - |
dc.title | Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: Biodistribution, pharmacokinetic and cytotoxicity study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Ki-Hyun | - |
dc.identifier.doi | 10.1088/2057-1976/ab73f7 | - |
dc.identifier.scopusid | 2-s2.0-85082002783 | - |
dc.identifier.bibliographicCitation | Biomedical Physics and Engineering Express, v.6, no.2, pp.1 - 18 | - |
dc.relation.isPartOf | Biomedical Physics and Engineering Express | - |
dc.citation.title | Biomedical Physics and Engineering Express | - |
dc.citation.volume | 6 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 18 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | gemcitabine | - |
dc.subject.keywordPlus | iron derivative | - |
dc.subject.keywordPlus | metal organic framework | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | area under the moment curve | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | drug bioavailability | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug clearance | - |
dc.subject.keywordPlus | drug cytotoxicity | - |
dc.subject.keywordPlus | drug delivery system | - |
dc.subject.keywordPlus | drug distribution | - |
dc.subject.keywordPlus | effective concentration | - |
dc.subject.keywordPlus | elimination half-life | - |
dc.subject.keywordPlus | encapsulation | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | IC50 | - |
dc.subject.keywordPlus | in vitro study | - |
dc.subject.keywordPlus | in vivo study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | maximum plasma concentration | - |
dc.subject.keywordPlus | mean residence time | - |
dc.subject.keywordPlus | MIA PaCa-2 cell line | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | PANC-1 cell line | - |
dc.subject.keywordPlus | rat | - |
dc.subject.keywordPlus | slow drug release | - |
dc.subject.keywordPlus | time to maximum plasma concentration | - |
dc.subject.keywordPlus | volume of distribution | - |
dc.subject.keywordAuthor | biodistribution | - |
dc.subject.keywordAuthor | encapsulation | - |
dc.subject.keywordAuthor | gemcitabine | - |
dc.subject.keywordAuthor | metabolic protection | - |
dc.subject.keywordAuthor | metal-organic frameworks | - |
dc.subject.keywordAuthor | pharmacokinetic | - |
dc.subject.keywordAuthor | release kinetics | - |
dc.identifier.url | https://iopscience.iop.org/article/10.1088/2057-1976/ab73f7/pdf | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.